Carlsquare A/S acted as financial advisor to Serendex Pharmaceuticals A/S in connection with a pre-emptive rights issue.
Serendex Pharmaceuticals A/S (OB:SENDEX) has successfully completed a pre-emptive rights issue with preferential rights for existing shareholders.
The rights issue resulted in gross proceeds of NOK 111.8 million and the new shares were admitted to trading and official listing at Oslo Axess in January 2016.
The completion of the rights issue was important in order to strengthen the company’s financial situation.
Carlsquare A/S acted as financial advisor to Serendex Pharmaceuticals A/S in connection with the structuring and completion of the rights issue, preparation of the prospectus and the coordination of other advisers.
| Client: | Serendex Pharmaceuticals A/S |
